Sight Sciences Reports Q1 2026 Earnings with Revenue Growth and Narrowing Net Loss
Sight Sciences (SGHT) reported Q1 2026 earnings with total revenue of $19.7 million, a 13% increase driven by growth in both the Interventional Glaucoma and Interventional Dry Eye segments. The company reported a net loss of $13.0 million, or $0.24 per share, which narrowed from the previous year. Gross margin remained strong at 86%, and cash reserves stood at $85 million.
Topics: cash position debt dry eye financial performance glaucoma net loss patent litigation revenue